Navigation Links
Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial

more than 300 papers in peer-reviewed journals.

Dr. Low is Head of the Department of Microbiology at the Toronto Medical Laboratories and Mount Sinai Hospital. He is also Medical Director, Ontario Public Health Laboratories, Ministry of Health and Long-Term Care. He is a Professor at the University of Toronto in the Department of Laboratory Medicine and Pathobiology and Department of Medicine. He is currently Head of the Division of Microbiology in the Department of Laboratory Medicine and Pathobiology.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day antibiotic in late-stage clinical development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at http://www.advancedlifesciences.com.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, clinical trials, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
5. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
6. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
9. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
10. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
11. GSKS Pazopanib Shows Positive Results in Patients with Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
Post Your Comments:
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ...
(Date:1/15/2014)... 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... patent application concerning composition of matter, biological targets, mechanism ... cell death.  This patent application describes ... RNA molecules (VSRNAs) which interfere with the basic homeostatic ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Insulin Pump ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong acceptance ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... 11 Chimerix, Inc., a,biotechnology company developing orally ... initiated a multi-dose trial with its,lead drug candidate, ... will study the pharmacokinetics and safety of three ... "The high oral availability demonstrated by CMX001 in ...
... works with hospitals to help reduce spread of ... national forum on quality in,health care, Highmark officials ... designed to deal with Methicillin,Resistant Staphylococcus Aureus (MRSA). ... hospitals in western,Pennsylvania in identifying patients that have ...
Cached Medicine Technology:Chimerix Initiates a Multi-dose Clinical Trial of the Company's Lead Compound, CMX001, for the Treatment for Smallpox Infection 2Highmark Presents Work on MRSA Prevention at National Health Care Quality Conference 2
(Date:4/17/2014)... 2014 By discovering a new mechanism that allows ... researchers at UC Irvine and the Salk Institute have ... or prevent stroke-induced brain damage. , A complex and ... death and primary reason for disability in the U.S. ... and lets blood-borne material into the brain, causing the ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit ... issues, published a comprehensive review today examining the current ... virus. The review calls for improved global surveillance strategies ... the recent outbreak of Ebola in West Africa that ... countries of Guinea and Liberia. According to the ...
(Date:4/17/2014)... Spending time online has the potential to ward off ... according to research published online in The ... Sciences . In the article " Internet Use ... States: A Longitudinal Analysis ," the authors report that ... by 33 percent among their study sample. , ...
(Date:4/17/2014)... Council scientists and their partners have found that their ... the transmission of multiple sexually transmitted infections (STIs) in ... simplex virus 2 (HSV-2), and human papillomavirus (HPV). The ... gel is effective against multiple strains of HIV, and ... all three viruses of at least eight hours prior ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival is ... of the abdomen when treated with cytoreductive surgery ... a first-of-its-size analysis by physicians at Wake Forest ... the largest reported, single-center experience with cytoreductive surgery ... M.D., and analysis of 20 years, worth of ...
Breaking Medicine News(10 mins):Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Internet use may cut retirees' depression 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... RI A new study by Rhode Island Hospital ... eating disorders have limited clinical utility. Researchers recommend a ... eating disorder. , In the DSM-IV manual, bulimia and ... defined eating disorders. A third, binge eating disorder, is ...
... LOUIS, Feb. 5 Young Innovations, Inc.,(Nasdaq: YDNT ) ... 2007., Sales for the fourth quarter of 2007 were ... $24.8 million reported in the fourth,quarter of 2006. Income from ... 2006 to $5.1 million in the fourth quarter of,2007. Net ...
... A Road Taken Together, NORTH ADAMS, Mass., ... across the globe will join the National,Patient Safety ... 2-8. The theme of the week, Patient Safety: ... safer health care through partnership,among providers, patients, families ...
... retrieve long-lost details , , TUESDAY, Feb. 5 (HealthDay News) ... details hidden in the long-term memories of people with ... about whether long-term memory is always dependent on a ... the memory-processing center called the hippocampus. , This study, ...
... Percent Growth ... - Special ... Edwards Lifesciences,Corporation (NYSE: EW ), a world leader in products ... ended December 31, 2007 of $15.8 million, or $0.27 per diluted,share, compared ...
... AtriCure, Inc.,(Nasdaq: ATRC ), a medical device company ... its financial results for the fourth,quarter and full year ... AtriCure will host a conference call at 10:00 a.m. ... and full year 2007 results. A,live web cast of ...
Cached Medicine News:Health News:New Rhode Island Hospital study shows inadequate diagnostic criteria for eating disorders 2Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 2Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 3Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 4Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 5Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 6Health News:Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend 7Health News:Patient Safety Awareness Week March 2 to March 8, 2008 2Health News:Brain Injury May Not Erase Long-Term Memory 2Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 2Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 3Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 4Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 5Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 6Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 7Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 8Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 9Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 10Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 11Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 12Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 13Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 14Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 15Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 16Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 17Health News:AtriCure Announces Web Cast and Conference Call of Fourth Quarter and Full Year 2007 Financial Results 2
An enzyme-linked immuno-sorbent assay for the detection and quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Enzyme immunoassay for the quantitative determination of Gliadin-IgG antibodies in serum and plasma. This kit provides specific determination of gliadin antibodies by using highly purified gliadin....
... can operate with batches of 60 ... addition of optional Load/Unload Trays, and ... AX-4280 is a benchtop urine chemistry ... reliability providing the laboratory with a ...
... This Free Estriol ELISA kit is ... Estriol in human serum or plasma. This ... competitive ELISA. The samples, standards, and controls ... wells coated with anti-Estriol antibody. Free ...
Medicine Products: